Development of Positive Control for Hepatitis B Virus

Similar documents
Polymerase Chain Reaction

HE Swift Cloning Kit

Cat # Box1 Box2. DH5a Competent E. coli cells CCK-20 (20 rxns) 40 µl 40 µl 50 µl x 20 tubes. Choo-Choo Cloning TM Enzyme Mix

pgm-t Cloning Kit Cat. # : GVT202 Size : 20 Reactions Store at -20

Hetero-Stagger PCR Cloning Kit

Molecular Genetics Techniques. BIT 220 Chapter 20

pgm-t Cloning Kit For direct cloning of PCR products generated by Taq DNA polymerases For research use only Cat. # : GVT202 Size : 20 Reactions

peco TM -T7-nGST, Eco cloning Kit User Manual (Patent pending)

Ready_to_use Fast Seamless Cloning Kit. User Manual

Journal of Experimental Microbiology and Immunology (JEMI) Vol. 6:20-25 Copyright December 2004, M&I UBC

Application of Molecular Biology tools for cloning of a foreign gene

ITS Sequencing in Millepora. 10/09 Subcloning DNA Fragments into pbluescript Preparation of pbluescript Vector

Molecular Cell Biology - Problem Drill 11: Recombinant DNA

SUPPLEMENTARY MATERIAL AND METHODS

XXII DNA cloning and sequencing. Outline

Figure 1. Map of cloning vector pgem T-Easy (bacterial plasmid DNA)

Lecture Four. Molecular Approaches I: Nucleic Acids

BIOTECHNOLOGY. Sticky & blunt ends. Restriction endonucleases. Gene cloning an overview. DNA isolation & restriction

GenBuilder TM Plus Cloning Kit User Manual

GenBuilder TM Plus Cloning Kit User Manual

Cold Fusion Cloning Kit. Cat. #s MC100A-1, MC101A-1. User Manual

CHAPTER 5 PTP-1B CLONING AND RECOMBINANT PROTEIN EXPRESSION. Recombinant DNA technology has revolutionized molecular biology and

Hepatitis C Virus Genemer Mix

pbluescript II RI Predigested Vector

NZYGene Synthesis kit

STANDARD CLONING PROCEDURES. Shotgun cloning (using a plasmid vector and E coli as a host).

Molecular Techniques Third-year Biology

GenBuilder TM Cloning Kit User Manual

Construction of a Mutant pbr322 Using Site-Directed Mutagenesis to Investigate the Exclusion Effects of pbr322 During Co-transformation with puc19

Chapter 20 Recombinant DNA Technology. Copyright 2009 Pearson Education, Inc.

Construction of an enlarged puc19 vector with a rop gene designed to study plasmid maintenance in Escherichia coli

7.1 Techniques for Producing and Analyzing DNA. SBI4U Ms. Ho-Lau

ZR-96 Genomic DNA Clean & Concentrator -5 Catalog Nos. D4066 & D4067

Rapid amplification of cdna ends (RACE)

Data Sheet Quick PCR Cloning Kit

Genomic DNA Clean & Concentrator -25 Catalog Nos. D4064 & D4065

HELINI Hepatitis B virus [HBV] Real-time PCR Kit (Genotype A to H)

Table of contents. I. Flowchart of blunt end cloning of PCR products...2. II. Description...3. III. Kit Components...3

Selected Techniques Part I

Guide-it Indel Identification Kit User Manual

HCV Genotype Primer Kit

Mighty Cloning Reagent Set (Blunt End)

B. Incorrect! Ligation is also a necessary step for cloning.

Mighty Cloning Reagent Set (Blunt End)

Synthetic Biology for

Site-directed mutagenesis of proteins

Genomic DNA Clean & Concentrator -10 Catalog Nos. D4010 & D4011

KOD -Plus- Mutagenesis Kit

Chapter 10 (Part II) Gene Isolation and Manipulation

Table of Contents. i. Insertion of DNA fragments into plasmid vector...4. ii. Self-circularization of linear blunt-ended DNA...4

MOLECULAR BIOLOGY EXPERIMENT PCR & SEEDING

Conversion of plasmids into Gateway compatible cloning

YG1 Control. YG1 PstI XbaI. YG5 PstI XbaI Water Buffer DNA Enzyme1 Enzyme2

Ligation Independent Cloning (LIC) Procedure

California Institute of Technology. Directed evolution. Dr. F.H. Arnold s lab

Mighty TA-cloning Kit

Regulation of enzyme synthesis

INNOVAPI WP3 Activity 3 Health Parameters

DNA PURIFICATION KITS PLASMID DNA ISOLATION

HiPer Plasmid DNA Cloning Teaching Kit

HiPer RT-PCR Teaching Kit

Cat. # Product Size DS130 DynaExpress TA PCR Cloning Kit (ptakn-2) 20 reactions Box 1 (-20 ) ptakn-2 Vector, linearized 20 µl (50 ng/µl) 1

Fast and efficient site-directed mutagenesis with Platinum SuperFi DNA Polymerase

The Biotechnology Toolbox

Creating pentr vectors by BP reaction

DETECTION OF HEPATITIS C VIRUS RNA USING REVERSE TRANSCRIPTION PCR

pget1.1 Vector (50 ng/μl) 23 μl pget-for Primer (10 μm) 100 μl pget-rev Primer (10 μm) 100 μl

SuperTCRExpress TM Human TCR Vβ Repertoire CDR3 Diversity Determination (Spectratyping) and Quantitative Analysis Kit

Protocols for cell lines using CRISPR/CAS

HelixClone. PCR Cloning Kit. Simple and Fast technique for Cloning

Recombinant DNA Technology

Product Information GetClone PCR Cloning Vector II. Storage -20 C for 24 months

Gateway Cloning Protocol (Clough Lab Edition) This document is a modification of the Gateway cloning protocol developed by Manju in Chris Taylor's lab

Table of contents. I. Description II. Kit Components III. Reagents and Instruments Required IV. Storage V. Protocols...

DNA/RNA Protocols CLONING. Standard PCR set-up, per reaction. 50ul total volume/tube

CELLTECHGEN For Research Only. Construction of sgrna expression vector for Lenti-virus system (Example: Lenti-U6 sgrna-ef1 -Puro vector)

7.02 Recombinant DNA Methods Spring 2005 Exam Study Questions Answer Key

VDL101.3 CLONING TRANSGENE INTO pad5f35

Ligation high DNA Ligation Kit

Subcloning of the Bacteriophage B3 terminase gene into pucp20

Construction of pcxz14w, a Novel puc19-derived Plasmid Encoding the rop Gene

Amplification Products for PCR and RT-PCR

APPENDIX S1. The SSR-patchwork protocol for SSR libraries.

CHAPTER 20 DNA TECHNOLOGY AND GENOMICS. Section A: DNA Cloning

PureSpin DNA Clean Up Kit

Cloning of open reading frames encoding for wildtype and G145R HBsAg of hepatitis B virus in Escherichia Coli Jm109

Hepatitis B Virus Genemer Amplification Kit. Amplification premix for HBV Viral Specific Fragment

Cloning in bacteria. Presenter: Vito Baraka (BSc,MSc Cand.)

CELLTECHGEN For Research Only. Construction of all-in-one vector for Lenti-virus system (Example: Lenti-EF1 -Cas9-EGFP-U6 sgrna vector)

Polymerase Chain Reaction PCR

FMF NIRCA PROTOCOL STEP 1.

(Supplementary Methods online)

CLONING AND EXPRESSION OF PSEUDOMONAS AERUGINOSA PA01 GENES IN E.COLI DH5Α FOR THE DETECTION OF ARSENIC IN CONTAMINATED WATER SAMPLE

THE UNIVERSITY OF NEWCASTLE- DISCIPLINE OF MEDICAL BIOCHEMISTRY. STANDARD OPERATING PROCEDURE PROCEDURE NO: GLP 084 MOD: 1st Issue Page: 1 of 11

Generation of Non-typeable Haemophilus influenzae Directed Gene Deletion Mutants Jeroen D. Langereis *

Chapter 15 Recombinant DNA and Genetic Engineering. Restriction Enzymes Function as Nature s Pinking Shears

Taq + dntps #EZ U

ExactORF cdna Clones. Application Guide. Table of Contents

Transcription:

Human Journals Research Article December 2015 Vol.:2, Issue:2 All rights are reserved by Saurabh Bandhavkar et al. Development of Positive Control for Hepatitis B Virus Keywords: Hepatitis B virus, pbluescript, positive control ABSTRACT Saurabh Bandhavkar* Department of Biochemistry, G. S. Medical College and KEM Hospital, Mumbai, Maharashtra, India. Submission: 20 November 2015 Accepted: 27 November 2015 Published: 15 December 2015 www.ijsrm.humanjournals.com More than 2 billion people are believed to be infected with Hepatitis B virus at some point in their life and thus Hepatitis B is regarded as the most common form of chronic hepatitis worldwide. Around 15-40% of people infected with HBV develop HBV-related complications and approximately 25% die as a result of these complications. Major complications include cirrhosis and hepatic carcinoma. It is estimated that approximately 65 million people developing such complications will die of liver diseases. It is therefore essential to develop rapid screening methods for detection of this virus in early stages. Since HBV is infectious and spreads through blood, semen and other body fluids, it will be easy to detect the presence of this virus in these body fluids. This detection of virus can be confirmed if we have a standard for comparing it with, referred to as positive control. Thus, by using PCR techniques we isolated HBV from blood samples and developed positive control for the same through simple molecular biology techniques.

INTRODUCTION Various blood tests are available to detect HBV from blood which all uses the Hepatitis B blood panel. This panel generally consists of three tests - Test for Hepatitis B surface antigen HBsAg, test for Hepatitis B surface antibody HBsAb or anti-hbs and test for Hepatitis B core antibody HBcAb or anti-hbc. Of these three tests, the test for surface antigen directly detects the virus, further the surface antigens can be found in the blood within 6-16 weeks of infection whereas the antibodies require 60-150 days to develop, and thus is one of the earliest serological markers of HBV detection[1]. Another major advantage of targeting the surface antigen is that the gene coding for it, the S- gene, is quite conserved in all hepatitis B genotypes[2]. Due to the presence of three in-frame start (ATG) codons, the long open reading frame S-gene may be divided into three sections: pre- S1, pre-s2 and S. In this work, we targeted the S-gene by first identifying the conserved region in S-gene which is retained in all the hepatitis B genotypes using the NCBI Blast tool. After identifying this region, suitable primers were designed according to criteria s mentioned by Integrated DNA Technologies Primer Quest Tool. Once the primers were obtained, molecular cloning was carried out to develop positive controls. MATERIALS AND METHODS Invitrogen s viral RNA/DNA kit by Life Technologies, Qiagen s PCR Purification kit, Qiagen s Miniprep kit for plasmid isolation, Qiagen s Gel extraction kit, Ligase buffer, Taq polymerase, Taq buffer, T4 ligase, PEG, Luria Agar, Luria Broth, X-gal, Ampicillin, IPTG (iso-propyl thiogalactoside), Thermofisher s 100bp and 1 kb DNA ladder. Isolation of Viral DNA from blood 10 ml of blood was collected from a Hepatitis B confirmed patient in an EDTA blood vacutainer. It was allowed to stand for few hours so as to allow its contents to settle and then centrifuged at the speed of 2000 rpm to obtain plasma. 200ul of this plasma was then used to obtain the viral DNA using the Invitrogen s viral DNA kit. The DNA obtained was then quantified using UV spectrophotometer. Citation: Saurabh Bandhavkar et al. Ijsrm.Human, 2015; Vol. 2 (2): 1-5. 2

PCR amplification and purification Polymerase Chain Reaction was set up using the isolated DNA. Gene-specific primers targeting the specific region on the S-gene were used for amplification. Other requirements of PCR such as Taq buffer, MgCl 2, dntps, Taq Polymerase were also provided. Temperatures suitable for denaturation, annealing and renaturation were calculated using the Tm of primers and a PCR of 35 cycles was set up. The amplified product of the gene specific primers was checked for the size of 207bp on 2% agarose gel (with Ethidium bromide) using 100bp ladder. This product was then purified using PCR purification kit so as to remove impurities (Fig 1). Restriction Digestion of Vector The vector used for cloning was pbluescript KS II +. This phagemid is readily available and has certain advantages in cloning: pbluescript, like puc vectors, have a multiple cloning sites inserted in the Lac Z gene, thus offering bluewhite screening as an advantage for the selection of positive clones. pbluescript also has an origin of replication of the single stranded phage f1, which is related to the M13 phage vectors. This translates into that a cell harboring a recombinant phagemid if infected by f1 helper phage that supplies the single stranded phage DNA replication components; it will produce and package single stranded phagemid DNA. Further, this phagemid is flanked by two different RNA polymerase promoters, a T3 promoter at one end side and a T7 promoter at the other end. This is key because it enables one to isolate the double-stranded phagemid DNA and transcribe it in vitro with either of these two phage polymerases to produce pure RNA transcripts to coincide with either of the two different strands [3]. This phagemid vector was cut using restriction enzyme Eco RV. A control restriction digestion was performed prior to this and it was found that Eco RV cuts pbluescript in 15 minutes. Once restriction digested, vector pbluescript and purified amplicon of insert were loaded on a 2% Citation: Saurabh Bandhavkar et al. Ijsrm.Human, 2015; Vol. 2 (2): 1-5. 3

agarose gel (with ethidium bromide) and it was allowed to run at 75 mv for approximately an hour. Once the gel was 3/4 th run, the cut vector was checked for a size of 2961bp using a 1kb ladder, whereas the insert was checked for a size of 201bp. After checking for the appropriate size, that portion of gel was cut and the vector and insert were extracted using the Qiagen s Gel extraction kit (Fig 2). A ligation reaction was then set up accordingly. Ligation and transformation Since cloning was performed using blunt end ligation, PEG was a pre-requisite, since the addition of polyethylene glycol (PEG) to ligation reactions can promote ligation of blunt-ended fragments by macromolecular crowding. Further, the amount of ligase and insert was also increased to aid in blunt end ligation. Ligation was allowed to proceed for 1 hour at 22 o Celsius. Once the ligation reaction was complete, the ligation mixture was transformed into top 10 strains of E.coli. 10ul of this transformation mixture was then plated on X-gal containing agar plates and incubated at 37 0 C overnight. These plates were prepared using 400ml of Luria Agar so as to contain a final concentration of 40ug/ml of X-gal, 100 ug/ml of Ampicillin and 0.1mM of IPTG. The plated plates were then checked for transformants next day using the blue-white screening principle (Fig 3). White colonies which indicated that the gene must have been inserted in the phagemid were picked up and screened for confirmation. Screening of white colonies by vector and gene-specific primers 24 white colonies were screened by setting up a PCR using vector specific primers first. The primers chosen to amplify 201bp in wildtype pbluescript, whereas a region of 408bp (201 +207) in transformed pbluescript. This was checked using 100bp DNA ladder. Citation: Saurabh Bandhavkar et al. Ijsrm.Human, 2015; Vol. 2 (2): 1-5. 4

The positive clones (clones 2,7,13 as seen in Fig. 4) obtained using vector specific primers (those showing a size of 408bp) were confirmed using gene-specific primers, wherein they amplified a region of 207bp (Fig 5). These clones were confirmed positive and they were picked and grown overnight on a shaker at a speed of 225rpm in 10ml LB media containing 10ul ampicillin. Plasmid isolation was carried out the following day using Qiagen s miniprep kit and the DNA thus obtained was the positive control for HBV. RESULTS AND DISCUSSION Thus, positive controls targeting a small region of 207bp on the S-gene of Hepatitis B virus were successfully prepared by cloning into pbluescript KS II + using blunt end ligation. This method offers a simple method for development of positive controls which can be done in a week s span. Such positive controls help us to easily confirm patients having a Hepatitis B infection. This method thus, is less time consuming, very economical and requires no special scientific expertise. Furthermore, such positive controls can be prepared for various other viruses and can be used for their easy detection. ACKNOWLEDGEMENTS I would like to thank BioGenomics Limited (Manpada, Thane) for providing me with all the materials to carry out my project. REFERENCES 1. Raimondo G, Pollicino T, Squadrito G; Clinical virology of hepatitis B virus infection.j Hepatol 2003;39:S26- S30. 2. Naaz Abbas, Mohammad Ajmal and Talat Afroze, Primer designing for pre-s region of hepatitis B virus from the most conserved patches of hepatitis B virus genome; Journal of Bioinformatics and Sequence analysis, May 2014. 3. Brunel University Genome Project Webpage.17 Feb.1998. 15 Feb. 2003. <http://www.brunel.ac.uk/depts/bl/project/genome/moltec/vectors/phagemid.htm#option1> 4. pbluescript II Phagemid Vectors; Instruction Manual; Catalog #212205, #212206, #212207 and #212208 5. World Health Organization. Global alert and response: hepatitis B. Geneva, Switzerland: World Health Organization, Department of Communicable Diseases Surveillance and Response; 2014 Available at http://www.who.int/csr/disease/hepatitis/hepatitisb_whocdscsrlyo2002_2.pdf?ua=1 6. WHO position paper on hepatitis B vaccines - October 2009. Wkly Epidemiol Rec 2009;84:405-20. Citation: Saurabh Bandhavkar et al. Ijsrm.Human, 2015; Vol. 2 (2): 1-5. 5